Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
Sponsor: Rush University Medical Center
Summary
As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA reduces the postoperative reduction in hemoglobin, hematocrit, number of transfusions, and postoperative blood loss following open spine surgery. The regimen that utilizes multiple doses of oral TXA will significantly minimize post-operative blood loss and transfusion requirements compared to the use of a single dose regimen. Furthermore, oral TXA will be as efficacious as intravenous delivery of TXA.
Official title: Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
604
Start Date
2019-08-26
Completion Date
2027-01-01
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus)
Intravenous methods to decrease blood loss
Vitamin C 250 MG Oral Tablet
Oral method of placebo
Tranexamic Acid 650Mg Tablet
Oral method of treatment group
Locations (1)
Rush University Medical Center
Chicago, Illinois, United States